Gayer Charles K, an insider at BioCryst Pharmaceuticals Inc (BCRX), purchased 892,492 shares at $3.22 each on December 21, 2025, totaling approximately $2.87 million. Following this transaction, Gayer holds a total of 892,492 shares in the company.
BioCryst Pharmaceuticals, headquartered in Durham, North Carolina, operates within the biotechnology sector, employing 580 full-time staff. The firm specializes in developing first-in-class oral small-molecule and protein therapeutics aimed at challenging diseases. Its marketed products include ORLADEYO, an oral medication for preventing hereditary angioedema attacks, and RAPIVAB, an injection for treating acute uncomplicated influenza in patients six months and older.
The company's market capitalization stands at $1.4 billion, with a trailing twelve months (TTM) earnings per share (EPS) of -0.17. Upcoming earnings reports are scheduled for May 4, 2026, with an estimated EPS of $0.08 and revenue of $158.6 million, and August 3, 2026, with an estimated EPS of $0.09 and revenue of $173.2 million.
Insider transactions, such as this purchase, are reported to the SEC and can provide transparency regarding executive sentiment toward company stock. However, they should be viewed as one of many factors in investment analysis.